Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Liam don't think they would want chinese to produce it as they will only copy it. Why are you on here deramping a share which has already x3 and potential to do much more with a CE mark.
You are a sad individual trying to scare PI's into selling at a low price as everyone knows what is around the corner. How much are you paid to post?
Because of Fum past history it will be a miracle if Fum is succeeded to bring along any reputable Pharma on board to make success of MED 3000 and to make some money for everybody.
I've got to pull you up on one thing, MR.Space. You said FUM doesn't make these claims "alone" and you go on to quote our old chum Prof Ralph. As a KOL on the Futura European KOL Advisory Panel, he's not likely to disagree with any of FUM's claims. In fact, he probably authored several of them himself. I'm not discounting his statements by any means, but potential investors should be aware of his close links with the company.
All I see of the last poster is:
! This message has been filtered, please adjust your filters to view.
Totally agree with your synopsis MR Space. Facts are often drowned down by polluting noise. Balance is welcomed and useful to keep a level head. However, facts can often be trumped by (some may say 'deliberate') alternative facts.
1) CE mark approval received.
2) Far East production/distribution deal done and funded.
3) Years of past experience of this situation gained (Hopefully, now applied)
4) Already featured in main stream media. (Eagerly awaited on the shelves.)
4) FDA trial in the pipeline.
Whilst not a done deal, there's a lot to be optimistic about.
Oh oh I feel some links and a long post coming.
Let us hope you are right Spacetomato and Med 3000 will be a success and we all make some money.
sightwatcher, actually it is not futura that "claims" it alone by the way; Professor David Ralph, Consultant Urologist at University College London and past president of the European Society of Sexual Medicine said the following on MED3000 :
"The efficacy of MED3000 is remarkable and approaches the efficacy of current first line therapy but with significantly lower adverse events. With topical application, it will be of particular appeal to patients who want a fast onset of action. Lack of drug interactions with prescription products will enable the product to be used with other medications such as nitrates and other cardiovascular drugs. It can also potentially be used in conjunction with other ED products to improve overall efficacy to patients. As such the product will be of great interest to the medical community."
So, excuse me but there is one way, and one way only for FUM and that is to get the product on the market; and if that means to raise capital via placing, debt etc..so be it. We have product that can be bought, of you push it, together with the candies, soft drinks and condoms at the newsagents! We have a licence to print money if you ask me.
Yes, and $4bl will be peanuts for any major interestested in making money on a gel to massage your tinkie.
Come on..bring the CE marking ..$$$$$$$
It depends on MED 3000. If it is really effective as Fum claim then there is a remote possibility of buying out Fum. You never know no Pharma comes along at all really and hard work has to do itself by manufacturing, marketing and distributing the product and in this case it will be monumental task by Fum requiring lot of funds and expertise.
14 pharmaceutical acquisitions this year, as reported by Becker's Hospital Review:
Eli Lilly to acquire small California biotech for $1.1 billion
Eli Lilly acquired Dermira, a small Menlo Park, Calif.-based drugmaker that specializes in chronic skin conditions, for $1.1 billion.
Gilead acquires cancer biotech for $4.9B
Gilead acquired Menlo Park, Calif.-based cancer biotech Forty Seven for $4.9 billion.
CVS to acquire St. Louis grocery chain's pharmacy business
CVS Pharmacy acquired all 110 of St. Louis-based grocery store chain Schnucks' retail and specialty pharmacies.
J&J to acquire Momenta Pharma for $6.5B
Johnson & Johnson bought Cambridge, Mass.-based Momenta Pharmaceuticals for $6.5 billion, a move to strengthen the drugmaker's portfolio of autoimmune disease treatments.
Acadia Pharmaceuticals acquires Texas drugmaker for $52.5M
Acadia Pharmaceuticals acquired Fort Worth, Texas-based biotech CerSci Therapeutics for $52.5 million, a move that broadened the San Diego-based drugmaker's pain medication portfolio.
Nestle acquires Aimmune Therapeutics for $2.6B
Nestle paid $2.6 billion to acquire Brisbane, Calif.-based Aimmune Therapeutics, a move that broadens the Swiss food company's health science portfolio.
Bayer to acquire vitamin subscription company for $225M
Bayer will purchase Care/of, an online vitamin and supplement provider, in efforts to expand its nutrition and wellness portfolio.
Gilead expands oncology portfolio, acquires Immunomedics for $21B
Gilead purchased Immunomedics, a Morris Plains, N.J.-based cancer drugmaker, for $21 billion.
UnitedHealth acquires competitor to Amazon's PillPack
UnitedHealth Group acquired DivvyDose, a startup that delivers medications in presorted packages and competes with Amazon's PillPack.
Bristol Myers Squibb acquires MyoKardia for $13B
Bristol Myers Squibb inked a $13.1 billion deal to buy Brisbane, Calif.-based drugmaker MyoKardia, aiming to diversify its drug portfolio beyond oncology medicines.
Rite Aid to acquire Seattle-based pharmacy chain for $95M
Rite Aid acquired Seattle-based pharmacy chain Bartell Drugs for $95 million.
Bayer acquires gene therapy company for $4B
Bayer bought gene therapy company Asklepios BioPharmaceutical, commonly known as AskBio, in a deal totaling $4 billion.
Merck to acquire COVID-19 drug developer for $425M
Merck announced it will buy Rockville, Md.-based drugmaker OncoImmune for an upfront cash payment of $425 million to obtain rights to the drug it's developing for patients hospitalized with severe and critical COVID-19.
Gilead to pay $1.4B for hepatitis drugmaker
Gilead said it plans to buy German drugmaker MYR GmbH for $1.4 billion to gain access to its drug Hepcludex, which treats adults with chronic hepatitis delta virus infection.